Skip to main content
. 2019 Dec 2;9:18021. doi: 10.1038/s41598-019-54226-7

Figure 5.

Figure 5

SEC analysis. SEC elution profiles of (a) ranibizumab, (b) aflibercept, and (c) bevacizumab at D0 (black) and D7 (blue). Comparison of AUC (%) of peak A and B for samples of (d) aflibercept and (e) bevacizumab from D0 and D7. Ranibizumab (a) only displayed one peak. The data are presented as mean ± SD. For each sample set n = 6. The unpaired Student’s t-test was used for statistical analysis.